ACCELERATED PARTIAL BREAST IRRADIATION (APBI)


Accelerated Partial Breast Irradiation Therapy at FROS Radiation Oncology
Cyberknife Center in New York


5-Day Breast Cancer Treatment

At FROS our experienced doctors may administer APBI treatments via Accuboost HDR brachytherapy or through the Cyberknife Radiosurgery System.
With APBI, the radiation treatment is focused specifically on the part of the breast where the tumor was removed. This allows the radiation to be contained to the tumor cavity as much as possible. Because the radiation is so targeted, it affects less of the healthy tissue and organs close to the breasts, including the lungs, heart, ribs, muscles and skin.
At FROS this breast cancer treatment is given in a more condensed schedule than some other radiation therapies for breast cancer. APBI allows breast cancer to be treated with radiation therapy in five days instead of six to seven weeks.
Requirements for this type of treatment typically include a small tumor, clear surgical margins after a lumpectomy, and preferably no lymph nodes containing cancer. Thus, APBI may be a suitable treatment option for women with early stage breast cancer.

At FROS Radiation Oncology Cyberknife Center, our team is committed to bringing leading-edge technology with highly compassionate care to our patients.

Please call us at 1-888-880-6646 today to find the right treatment for you.

IN THE NEWS

August 28, 2013

June 1, 2013

FROS attending physicians, Alan Katz and Josephine Kang, to give an oral presentation at this year's ASTRO meeting on long term outcomes after stereotactic body radiation therapy (SBRT) for prostate cancer.

VIDEOS

The Redefining Radiosurgery Video gives definitive clinical, hospital and patient benefits as compared to other radiation therapy and systems.

Contribute!

LOCATIONS

Flushing: 40-22 Main St, 4th Fl,
Flushing, NY 11354
Brooklyn: 1737 Bath Ave
Brooklyn, NY 11214
Manhattan: 47 Essex St.
New York, NY 10002

STAY CONNECTED

Stay in touch with FROS Radiation Oncology & Cyberknife Centers. Join us on Facebook, Twitter and LinkedIn for latest news and info.